Evadol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evadol

Property Description
Active ingredient Diclofenac
Form Systemic or Topical Preparations
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic Compound (Phenylacetic Acid Derivative)

What Type of Medicine is Evadol?

Evadol is a pharmaceutical preparation primarily defined by its active ingredient, Diclofenac, which classifies it as a Nonsteroidal Anti-inflammatory Drug (NSAID). This high-level classification places it among agents that modulate inflammation, pain, and fever responses within the body. Diclofenac is a synthetic compound, chemically identified as a Phenylacetic Acid Derivative, distinguishing its structure from propionic acid-derived NSAIDs. The drug's core identity rests on its role as a single active ingredient product, ensuring its established therapeutic profile is rooted solely in the known actions of Diclofenac, a substance recognized for its anti-inflammatory properties.

Composition, Forms, and General Purpose

The composition of Evadol centers on Diclofenac and the necessary pharmaceutical excipients appropriate for its final presentation. Depending on the product, Evadol may be supplied as systemic preparations, such as tablets for oral intake, or as topical preparations like gels. This type of medicine works to decrease substances in the body that cause pain and inflammation. The general therapeutic purpose of Evadol is to offer symptomatic relief through its well-defined effects: providing an Anti-inflammatory effect by mitigating swelling, producing an Analgesic effect to lessen pain perception, and delivering Antipyretic action to reduce elevated body temperature.

Why Evadol is Classified as an NSAID

The NSAID classification is critical because it immediately communicates the medicine's fundamental mode of action as a reversible inhibitor of the Cyclooxygenase (COX) enzyme pathway. This enzymatic modulation distinguishes Evadol from basic pain relievers. The capacity to address both the pain (Analgesic effect) and its underlying biological source (Anti-inflammatory effect) simultaneously defines the comprehensive symptomatic utility inherent to the NSAID designation.

Regulatory References

  1. Diclofenac Oral Drug Information (MedlinePlus)
  2. Diclofenac Sodium Monograph (DailyMed/NLM)

What side effects are possible with Evadol?

Possible side effects and safety information

The safety profile of Evadol (Diclofenac) is defined by officially documented risks and regulatory classifications inherent to its designation as a Nonsteroidal Anti-inflammatory Drug (NSAID). Adverse reactions are formally grouped by frequency and affected body systems, as established by governmental health authorities.


Frequency and System-Organ Classes

Adverse effects are categorized based on their incidence in clinical use. Common effects, reported in up to 1 in 10 patients, frequently involve the Gastrointestinal System (e.g., dyspepsia, nausea, abdominal pain) and the Nervous System (e.g., headache, dizziness). Less frequent, Very Rare effects may involve severe Dermatological Reactions (e.g., Stevens-Johnson syndrome) or Acute Renal Failure.


Serious Adverse Reactions and Safety Constraints

The official label documents an increased risk of serious, potentially fatal Cardiovascular Thrombotic Events (Myocardial Infarction, Stroke) and Gastrointestinal Adverse Events (Bleeding, Ulceration, Perforation). This risk is associated with long-term use and higher systemic doses.

Safety constraints include absolute contraindications, such as for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery. Specific Population-Specific Safety Considerations are noted for Older Adults, who face a greater risk of serious GI events, and for patients with pre-existing cardiac or hepatic impairment.


Regulatory Safety Summary

  • The safety profile is defined by an officially documented, increased risk of serious cardiovascular and gastrointestinal events.
  • Adverse reactions are formally categorized by frequency and grouped into System-Organ Classes, with Gastrointestinal disorders being the most frequently reported class.
  • Specific contraindications (e.g., post-CABG) and population-specific risk increases (e.g., in older adults) are explicitly defined in the regulatory label.

Overdose and Emergency Response

Evadol (Diclofenac) overdose may present with documented clinical signs that include nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Central nervous system manifestations such as drowsiness, dizziness, lethargy, headache, or tinnitus (ringing in the ears) are also officially noted in regulatory documentation.

Immediate medical attention must be sought if an overdose is suspected. Regulatory guidance mandates contacting a local poison control center or emergency services immediately. Urgent medical help is specifically required for signs of severe or life-threatening outcomes, including seizures, coma, severe allergic reactions, or evidence of acute renal failure (e.g., little or no urine output) or hepatic damage.

The official regulatory profile confirms that no specific antidote is known for Evadol overdose. Management is symptomatic and supportive treatment, focused on addressing the clinical effects. Procedures such as administering activated charcoal or gastric lavage may be considered if a potentially toxic amount was recently ingested. Due to the risk of severe complications, continuous hospital monitoring of vital signs, renal function, and hepatic function may be required, particularly in elderly patients or those with pre-existing organ impairment.

Therapeutic Uses of Evadol

What Evadol Treats: Main Uses and Benefits

Evadol (Diclofenac) is commonly used to help with symptoms related to physical discomfort across key therapeutic domains, providing support that helps ease the overall symptom burden in clinical contexts where symptoms that interfere with daily functioning become noticeable. The medication is applied in scenarios where additional management of discomfort is required.

The medication is considered relevant for managing symptoms associated with conditions involving inflammatory or irritative processes, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also applied in conditions associated with acute or disruptive episodes like migraine attacks and primary dysmenorrhea. It is commonly used across domains where additional symptomatic support is needed for specific localized situations, including post-operative inflammation and Actinic Keratosis.

“The primary role of Evadol is offering supportive relief that helps patients cope more steadily with symptom fluctuations during difficult episodes.”


Chronic Disease Symptom Management

Evadol is commonly used across conditions characterized by periods of heightened symptoms, where it plays a role in managing symptom clusters that may become intense, such as persistent joint pain, stiffness, and swelling. This support assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Joint Stiffness and Swelling

Evadol contributes to improved comfort during periods of heightened symptoms by addressing the specific symptoms related to inflammatory or irritative states that often characterize musculoskeletal conditions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Evadol?

Eligibility for Evadol (Diclofenac) is strictly defined by government regulatory documents, focusing on absolute contraindications and specific population restrictions.

Contraindicated Populations (Must Not Use)

Evadol is strictly contraindicated for individuals with a known hypersensitivity to the active ingredient or who have a history of allergic reactions, such as asthma or urticaria, after taking aspirin or other NSAIDs. Use is also prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Absolute non-eligibility extends to patients with active gastrointestinal bleeding or perforation, and those with severe hepatic, renal, or advanced heart failure (NYHA Class II-IV). These are formal exclusions defined in official prescribing information.

Age and Life Stage Restrictions

The medicine is contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation) due to documented fetal risks, and use is generally not recommended during breastfeeding for systemic formulations. For pediatric patients, safety and effectiveness are often not established in children under 12 years of age. Older adults are eligible but require caution, often necessitating lower doses due to an increased risk of gastrointestinal and kidney complications.

Conditional Eligibility

Individuals with mild to moderate impairment of the liver or kidneys, or a history of prior stomach ulcers, may be eligible, but use is restricted and requires close medical supervision and monitoring. These limitations are mandated by regulatory authorities to manage specific risks associated with the NSAID class.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Evadol, which contains an estrogen, is subject to specific drug-drug interactions that may alter its effectiveness or increase the risk of side effects. These interactions generally fall into two categories: those affecting metabolism and those involving combined effects on the blood clotting system.

Metabolic Interactions

Evadol is metabolized partially by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Products that induce this enzyme, such as rifampin, phenobarbital, carbamazepine, and St. John's Wort preparations, may decrease the circulating plasma concentrations of Evadol. This reduction could lead to a loss of the product's therapeutic effect. Conversely, strong CYP3A4 inhibitors, including ketoconazole, itraconazole, erythromycin, clarithromycin, and ritonavir, may increase Evadol plasma concentrations, potentially resulting in enhanced side effects.

Coagulation and Other Interactions

The product may affect the activity of anticoagulants (blood thinners), potentially decreasing their effect. Evadol may also increase the risk of thrombogenic (clot-forming) activities when combined with various antineoplastic/immunological agents. For patients taking other hormonal agents like anastrozole, Evadol may decrease the therapeutic efficacy of the co-administered product. Patients should inform their healthcare provider about all medicines, over-the-counter products, and herbal supplements they use.

Mechanism of Action

The mechanism of Evadol (Diclofenac) is defined by its ability to interfere with a central enzyme system that regulates biochemical signaling involved in inflammatory, nociceptive, and febrile processes. This action is precise, molecular, and leads directly to three distinct physiological outcomes.

Enzymatic Blockade of Prostaglandin Synthesis

Evadol functions as a reversible non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). By blocking these enzymes, the drug truncates the Arachidonic Acid Cascade, thereby suppressing the production of key local chemical mediators, particularly prostaglandins, which mediate local tissue responses, including vasodilation and increased vascular permeability.

Modulating Peripheral Pain Sensitization

This mechanism involves modulating the factors that lead to the amplification of nociceptive signaling. By reducing prostaglandin E2 ( PGE2) at the site of tissue stress, the drug lowers the chemical environment that usually sensitizes peripheral nerve endings (nociceptors). This action results in a state of decreased sensitivity within the peripheral pain pathway, leading to a predictable physiological adjustment that reduces the hypersensitivity of nociceptors.

Central Resetting of the Thermal Set-Point

The same enzyme-blocking mechanism occurs in the hypothalamus, the brain's temperature control center. Suppressing PGE2 synthesis in this area removes the signal that pathologically elevates the body’s thermal set-point. This allows the core regulatory system to restore normal temperature, resulting in a physiological effect that reverses the pathological elevation of the thermal set-point by enabling heat-dissipation mechanisms.

Dosage and Administration Information

How Evadol is Used: Official Administration Guidelines

Administration of Evadol (Diclofenac) involves specific routes, dosing schedules, and administration conditions across its various preparations.


Administration Scope

The medicine is available in multiple forms, with administration methods ranging from systemic to localized use:

  • Routes of Administration: Methods include Oral (tablets, capsules, powder for solution), Topical (gels, solutions), Intravenous (IV) injection/infusion, Intramuscular (IM) injection, and Rectal suppositories.

  • Dosing Schedule: For chronic conditions like Osteoarthritis, the oral dose often ranges from 100 mg to 150 mg total daily dose, typically administered in divided doses for Delayed-Release (DR) forms, or once daily for Extended-Release (ER) forms. The maximum daily oral dose is generally limited to 150 mg to 225 mg, depending on the specific formulation and indication.


Procedural and Timing Constraints

Instructions detail precise methods for intake to ensure proper action:

  • Preparation and Handling: Delayed-Release and Extended-Release oral tablets must be swallowed whole and must not be crushed, split, or chewed. The powder for oral solution must be mixed only with water (e.g., 30 to 60 mL) and consumed immediately after preparation.

  • Timing: For certain immediate-release oral forms and the powder solution, guidance suggests intake on an empty stomach to prevent reduced or delayed absorption. In contrast, other forms may be taken with food.

  • Duration Principle: A general principle is that Evadol must be used at the lowest effective dose for the shortest duration necessary to achieve the desired outcome.

  • Population Adjustments: For older adults, treatment is typically initiated at the lowest end of the dosing range due to general increased sensitivity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Evadol

The clinical understanding of Evadol (Diclofenac) is built upon a foundation of research that primarily includes Randomized Controlled Trials (RCTs), large-scale systematic reviews, and meta-analyses. These studies focus on documenting changes in specific patient-reported outcomes related to discomfort, stiffness, and physical activity across its evaluated uses.


Evidence for Symptomatic Management of Chronic Arthritis

Research on Evadol for arthritis focuses on outcomes linked to inflammatory or irritative states and functional limitations. Clinical evaluation is conducted using specific measurement scales to track short-term changes.

Studies on Pain and Function in Osteoarthritis

The research base for symptomatic relief in Osteoarthritis (OA) involves numerous short- to medium-term RCTs that have explored both oral and topical preparations of the active ingredient. These trials primarily compare the substance against an inactive placebo or, in some cases, other commonly studied agents. The main outcomes related to physical discomfort that were measured include changes in pain intensity and measured changes in physical function. Follow-up durations were limited in many studies, and there is noted variability in findings across different topical formulations of the medicine.

Studies on Symptom Activity in Rheumatoid Arthritis

For Rheumatoid Arthritis (RA), the research is relevant in trials assessing short-term or episodic symptom patterns. These investigations, often short-term RCTs, were conducted during periods of increased symptom activity and focused on adult patients with symptomatic RA. The outcomes monitored included specific counts of swollen and tender joints, and the duration of morning stiffness. Research does not focus on disease modification or long-term disease progression, as these outcomes are the subject of other therapeutic classes.


Evidence for Conditions Involving Acute Symptoms and Spinal Pain

Research into Ankylosing Spondylitis and Spinal Function

Evadol was studied for conditions marked by functional limitations and was evaluated in patients with Ankylosing Spondylitis (AS). Research examined specific outcomes related to physical discomfort and functional imbalance, such as changes in spinal stiffness and scores reflecting daily functioning. The long-term effects related to spinal function maintenance are not fully established.

Evaluation of Acute Pain Relief

Evadol was studied for conditions associated with acute or disruptive episodes, such as short-term injuries like sprains, strains, and post-operative inflammation. Research explored short-term symptom changes and assessed rapid outcomes related to physical discomfort. The research provides insight into short-term changes and findings describe patterns observed in the studies that were consistently documented across various types of acute injury.


What is Still Uncertain in the Research Landscape

Several limitations apply to the overall research landscape for Evadol: Long-term effects related to sustained functional measures in chronic conditions are not fully established through extended controlled trials. Comparative evidence comparing the numerous different formulations remains heterogeneous and, in some cases, lacking sufficient standardization. Data for certain groups (e.g., specific subgroups of patients with varying comorbidities) remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Evadol (FAQ)


Q: How quickly does Evadol usually start to have an effect?

Clinical studies and official documents indicate that the immediate-release formulations of Evadol may begin to provide meaningful symptomatic relief starting around 30 minutes after administration. The precise time until the full peak effect is achieved may vary depending on the specific formulation being used.


Q: Does Evadol cause weight gain?

According to official product information, rapid weight gain is sometimes listed as an infrequent or less common side effect. This weight change is often associated with fluid retention, which is medically referred to as edema.


Q: Is it possible to become dependent on Evadol?

The active ingredient in Evadol, Diclofenac, is a Nonsteroidal Anti-inflammatory Drug (NSAID). Official sources and regulatory bodies generally state that it is not scheduled as a controlled substance and is generally not associated with a risk of dependence or misuse.


Q: What happens if I forget to take Evadol?

Official instructions generally advise taking the missed dose as soon as it is remembered. However, if it is nearly time for a subsequent scheduled dose, official instructions note that the missed dose is typically skipped, and the individual resumes the regular schedule. Regulatory guidance advises against taking two doses at once.


Q: What should I do if Evadol does not seem to be working?

Regulatory guidelines for chronic conditions emphasize that a patient's need for symptomatic relief and response to Evadol should be re-evaluated periodically by a healthcare provider. Official guidance indicates that individuals should discuss their symptoms with their healthcare provider for a review of their therapeutic approach.


Q: Do I need to avoid driving while taking Evadol?

Official product labels advise caution regarding driving or operating machinery while using Evadol. This is due to reported side effects such as dizziness, drowsiness (somnolence), and temporary visual disturbances. Regulatory documents indicate that if these effects occur, activities requiring mental alertness, such as operating vehicles or heavy equipment, should be avoided.


Q: Does Evadol have a warning about affecting mood or behavior?

Official product labels list psychiatric disorders under the less common or very rare adverse effects. These rare reports can include changes in mood or behavior such as nervousness, depression, insomnia, and irritability.


Q: Is it common to feel tired when starting Evadol?

Official product information notes that certain nervous system effects are common, such as dizziness. While overall fatigue or tiredness is not typically listed among the most common effects, related symptoms like somnolence (drowsiness) are noted under the less frequent or common effects.


Q: How long does Evadol stay in the body?

According to official pharmacokinetics data, the terminal half-life of Evadol (diclofenac) in the plasma is short, typically reported as approximately one to two hours after systemic administration. The half-life is the time it takes for the concentration of the medicine in the body to be reduced by half.


Q: Is Evadol known to cause hair loss?

Hair loss, or alopecia, is occasionally listed in the official product information. Regulatory documents categorize this as a very rare post-marketing dermatological adverse reaction, meaning it has been reported infrequently after the medicine was released to the market.


Q: Do I need any special monitoring (like blood tests) while on Evadol?

Official guidelines recommend periodic monitoring, such as blood tests, particularly for patients receiving long-term therapy with this class of medication. This testing is advised to check kidney function, liver function, and blood counts.


Q: Is Evadol safe to take with alcohol?

Regulatory warnings indicate that using Evadol while consuming alcohol can significantly increase the risk of serious gastrointestinal side effects. This combination heightens the risk of complications such as stomach bleeding and ulceration.


Q: Does the effectiveness of Evadol decrease over time?

Official product information states that the patient's response to therapy should be re-evaluated periodically when the medicine is used for chronic conditions. This principle allows the healthcare provider to adjust the therapeutic approach if the effectiveness appears to change over time.


Q: What happens when you stop taking Evadol?

Evadol is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not associated with withdrawal effects. After stopping treatment, the therapeutic action of the active ingredient will simply wear off, which typically occurs within about 15 hours to 1 to 2 days.


Q: Is there a known antidote for Evadol overdose?

The official overdose section in regulatory documents confirms that there is no specific antidote for an overdose of Evadol. Management for overdose focuses solely on supportive care, which means treating symptoms and providing necessary medical support.


Q: What is the purpose of the different strengths of Evadol?

Different strengths of Evadol are manufactured to address various approved conditions and allow for flexibility in individualizing treatment. Regulatory guidance requires that the lowest effective dose be used, and the availability of different strengths enables prescribers to meet this requirement.


Q: Can Evadol make me more sensitive to the sun?

Official product information lists photosensitivity reactions as an uncommon or rare side effect. This reaction is an increased sensitivity to sunlight that can lead to a more severe sunburn or rash. The warning is noted particularly for the use of topical formulations.


Q: Is Evadol listed as a controlled substance?

No, Evadol (Diclofenac) is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not scheduled or classified as a controlled substance in the major regulatory jurisdictions.


How should Evadol be stored and disposed of?

Evadol (Diclofenac) must be stored and disposed of according to specific regulatory requirements to maintain its effectiveness and ensure public safety.

Official Storage and Handling

Requirement Constraint Defined in Official Labeling
Temperature Store at controlled room temperature, typically 20 C to 25 C. Keep from freezing and excessive heat.
Protection Keep in a closed container, away from direct light and moisture.
Child Safety Must be stored out of the reach and sight of children and secured.

Official Disposal Rules

Disposal must follow established procedures. The preferred method is to return unused or expired Evadol to a drug take-back program or utilize a mail-back envelope. If no take-back option is available, the medicine must be removed from its original packaging, mixed with an undesirable substance (e.g., dirt, used coffee grounds), placed in a sealed container, and then thrown in the household trash. Do not flush the medication down the toilet or release it to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Evadol found in:

A-Z Index: